All In Biotech

Drug Trial Radar · NCT06297525

Study of STP938 (Dencatistat) in Advanced Solid Tumours

An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Aug 2, 2024

Primary completion

Dec 2026

Study completion May 2027

Sponsor

Lead sponsor
Step Pharma, SASIndustry
Sponsor type
Industry
First posted
Mar 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.

Conditions

  • Solid Tumor

Interventions

  • STP938Drug

    Small molecule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: Through study completion, an average of 6 months

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Comprehensive Hematology Oncology, LLC

    St. Petersburg, Florida · Recruiting

  • Mary Crowley Cancer Research Center

    Dallas, Texas · Recruiting

  • Next Oncology

    San Antonio, Texas · Recruiting

  • Institut Gustave Roussy

    Villejuif, Paris, France · Recruiting

  • University College London

    London, United Kingdom · Recruiting

  • The Christie

    Manchester, United Kingdom · Recruiting

  • The Beatson Institute for Cancer Research

    Glasgow, Glasgow, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.